secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001213900-26-046411
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics presents AACR posters on stenoparib for colorectal cancer and ovarian cancer survival
--------------------------------------------------------------------------------

- Poster 2: stenoparib blocks WNT/β-catenin signaling and inhibits growth of colorectal cancer cell lines at clinically relevant concentrations.
- Poster 1: Highest stenoparib DRP® scores are associated with enhanced overall survival in phase 2 ovarian cancer trial (NCT03878849).
- CEO Thomas Jensen highlights stenoparib potential in colorectal cancer, a large area of unmet need in oncology.
- DRP® companion diagnostic platform may identify patients most likely to achieve extended survival with stenoparib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026046411/0001213900-26-046411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390026046411/ea0287156-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-046411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer